Cynthia Schwalm, President and CEO of Ipsen North America said “To date, somatostatin analogs are approved to manage symptoms of GEP NETs and are not approved as anti-tumor therapy. Somatuline® is the first and only somatostatin analog to demonstrate a statistically significant improvement in progression free survival in GEP NET in a large, multinational study clinical trial."
This is great for Ipsen USA, with new leadership it could not get better
Aucun commentaire:
Enregistrer un commentaire